肿瘤细胞治疗研究
英文原题：Severe dual fungal infection after bispecific antibody therapy: A case of invasive aspergillosis and mucormycosis in immunocompromised patient.
双特异性抗体是血液病的一种新疗法，尤其适用于淋巴瘤、骨髓瘤和急性淋巴细胞白血病。
双特异性抗体是血液病的一种新治疗方法，尤其是对淋巴瘤、骨髓瘤和急性淋巴细胞白血病。这类治疗呈现出与 CAR-T 细胞相同的免疫介导性副作用。然而，感染性并发症仍然是主要关注点，并伴有相关死亡率。真菌感染在临床试验中很少报告，但仍是一个主要关注点。我们报告一例弥漫性大 B 细胞淋巴瘤（DLBCL）患者在接受双特异性抗体 epcoritamab 治疗后发生曲霉和毛霉共感染的病例。该患者出现严重的细胞因子释放综合征（CRS）以及随后的真菌感染，由于免疫功能低下患者管理和共感染的复杂性，这些感染的诊断和治疗具有挑战性。包括 PET-CT 在内的先进诊断技术以及抗真菌联合治疗对于实现缓解至关重要。该病例强调了在类似高危患者中早期诊断、多学科管理和创新治疗策略的必要性。
Bispecific antibody is a new treatment for hematological disease, especially for lymphoma, myeloma and acute lymphoblastic leukemia. This class of treatment presents the same kind of side effect as CAR-T cell which are immune-mediated. Nevertheless, infectious complication remains a major concerns with related mortality. Fungal infection are rarely reported in clinical trial but remains a major concern. We report a case of a co-infection of Aspergillus and Mucorales in a patient with diffuse large B-cell lymphoma (DLBCL) following treatment with the bispecific antibody epcoritamab. The patient developed severe cytokine release syndrome (CRS) and subsequent fungal infections, which were challenging to diagnose and treat due to the complexities of managing immunocompromised patients and co-infection. Advanced diagnostics, including PET-CT, and a combination of antifungal therapies were crucial in achieving remission. The case underscores the need for early diagnosis, multidisciplinary management, and innovative treatment strategies in similar high-risk patients.
MEMBER ACCOUNT
登录成功会直接打开下一页。
